Use of C-reactive protein to predict the outcome of medical management of tuboovarian abscesses.
Medical management of tuboovarian abscesses (TOAs) has been shown to be successful. However, the ability to predict which patients with TOA would respond to antibiotic therapy could shorten the hospital stay and decrease treatment costs. C-reactive protein (CRP), an acute-phase-reactant protein with a short half-life, was investigated as a possible predictor of response by TOA patients to medical therapy. Twenty-two patients with TOAs were admitted prospectively into this study, which included daily quantitative determinations of CRP. The patients had either resolution of the mass and symptoms (responders), increased evidence of systemic sepsis and acute peritonitis requiring surgery (failures) or continuation of the tender adnexal mass without evidence of peritoneal irritation (persisters). Twelve patients classified as responders showed a continued daily decrease in quantitative CRP levels of at least 20% per day below the previous day's value until the return to normal levels. The five failures showed a progressive rise in CRP levels as well as evidence of systemic sepsis. Persisters showed an initial decrease in the CRP level followed by a leveling off of the value to a decrease of less than 20% per day. The rate at which daily CRP determinations decline may be a useful predictor of the response to antibiotic therapy.
Mercer
L J
LJ
Department of Obstetrics and Gynecology, University of Chicago Hospitals, IL.
Hajj
S N
SN
Ismail
M A
MA
Block
B S
BS
D000038:Abscess / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D006801:Humans; D008991:Monitoring, Physiologic; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy* / Q000378:metabolism; D011237:Predictive Value of Tests; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D002097:C-Reactive Protein